VTGN ▲ +13.0% - Vistagen Therapeutics, Inc. $VTGN - Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Vistagen Therapeutics rose 13.0% after announcing preliminary positive data from the open-label extension of its PALISADE-4 Phase 3 trial evaluating fasedienol for acute social anxiety disorder treatment. The positive results from the extension phase suggest the company's lead candidate is performing well in the ongoing study, which likely improved investor confidence in the drug's commercial potential. 22-SEP-2026 08:30 AM ET